The company reported high marks across several quality categories, including a five-star rating for medication reviews in its care for older adults programs. Functional status assessments for the same demographic earned 4.03 stars, while the company’s track record on all-cause readmissions—a metric tracking unplanned hospital returns—reached 4.77 stars.

Beyond clinical outcomes, Aetna maintained ratings above four stars in consumer-facing areas such as healthcare quality, customer service, and grievance management regarding drug plans. Despite these operational results, CVS Health shares fell 2.7% to $85.47 in after-hours trading following the announcement.